Despite strong revenue growth and cost reductions, the EPS miss and going concern warning may pressure shares short-term. Monitor the upcoming conference call for clarity on funding runway and licensing deal progress, which could provide upside catalysts.
Price Chart
Executive Summary
VolitionRx reported full-year 2025 revenue of $1.7M (40% YoY growth) and Q4 revenue growth of 133%, but posted a net loss with EPS of -$0.05, missing consensus of -$0.04. The company highlighted progress in licensing discussions and secured $8.3M in post-year-end funding, though its auditor issued a going concern warning.
Key Financial Metrics
Key Facts
- Full-year 2025 revenue was $1.7M, up 40% from 2024
- Q4 2025 revenue grew 133% YoY
- Net loss for the year was down 14% vs 2024
- Net cash used in operating activities was $19.7M, down 24%
- Subsequent to year-end, raised $8.3M in non-dilutive and equity funding
- Auditor's opinion includes going concern uncertainty
- EPS of -$0.05 missed consensus of -$0.04 by 25%
Financial Impact
EPS miss of -$0.01 (25% worse than expected) on revenue of $1.7M (40% above prior year)
Risk Factors
- Going concern qualification in auditor's report raises solvency concerns
- Persistent losses and cash burn despite revenue growth
- Reliance on future financing to sustain operations
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001477932-26-001830 |
| Document: vnrx_ex991.htm | 0001477932-26-001830 |
| Document: 0001477932-26-001830-index-headers.html | 0001477932-26-001830 |
| Document: 0001477932-26-001830-index.html | 0001477932-26-001830 |
| Document: 0001477932-26-001830.txt | 0001477932-26-001830 |
| 8-K Data (Synthetic) | 0001477932-26-001830 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 25, 2026 4w ago | 8-K | $0.2529 | awaiting T+60 | — | $0.1800 (+28.83%) |
Sep 16, 2026 5w ago | SC 13D/A | $0.2849 | awaiting T+60 | — | $0.1800 (−36.82%) |
Sep 15, 2026 5w ago | 8-K | $0.2749 | awaiting T+60 | — | $0.1800 (+34.52%) |
Sep 11, 2026 6w ago | EFFECT | $0.3102 | awaiting T+60 | — | $0.1800 (+41.97%) |
Sep 8, 2026 6w ago | S-3/A | $0.3400 | awaiting T+60 | — | $0.1800 (+47.06%) |
Sep 1, 2026 7w ago | 8-K | $0.3800 | awaiting T+60 | — | $0.1800 (+52.63%) |
Aug 24, 2026 9w ago | 8-K | $0.3846 | awaiting T+60 | — | $0.1800 (+53.20%) |
Aug 7, 2026 11w ago | 8-K | $0.7700 | awaiting T+60 | — | $0.1800 (+76.62%) |
Jul 20, 2026 14w ago | EFFECT | $1.13 $0.1847 | ▲ +83.65% | ▲ +88.50% | $0.1800 (+84.07%) |
Jun 18, 2026 18w ago | 8-K | $1.34 | awaiting T+60 | — | $0.1800 (+86.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers